Chronic Hand Eczema and Other Regional Eczemas
The FDA’s approval of delgocitinib for chronic hand eczema is shining a light on this and other regional eczemas. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Peter A. Lio, MD, FAAD, clinical assistant professor of dermatology and pediatrics at the Northwestern University Feinberg School of Medicine. Watch as Dr. Lio shares the burden of chronic hand eczem …
The FDA’s approval of delgocitinib for chronic hand eczema is shining a light on this and other regional eczemas. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Peter A. Lio, MD, FAAD, clinical assistant professor of dermatology and pediatrics at the Northwestern University Feinberg School of Medicine. Watch as Dr. Lio shares the burden of chronic hand eczem … Continue reading "Chronic Hand Eczema and Other Regional Eczemas"
Dermatologists treat more than 3,000 conditions, but not all of them receive equal attention. In this Next Steps in Derm video interview, in partnership with the ODAC Dermatology Conference, ODAC Conference Co-Chair Adam Friedman, MD, FAAD, addresses common, yet overlooked skin conditions, most of which do not have FDA-approved therapies. Watch and learn tips for the creative management of lichen … 
Introducing the April 2024 Editorial Highlights from the Journal of Drugs in Dermatology! This month's issue is packed with groundbreaking research and insights into dermatologic treatments and practices. From original articles exploring innovative therapies for conditions like photoaging and acne vulgaris to case reports shedding light on rare dermatologic phenomena, this issue offers a comprehen … 
The October 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on atopic dermatitis and features mix of original articles, letters to the editor, and case reports. Among many of the topics explored in this issue are statins for treating actinic porokeratosis, ant venom-based ceramide therapy, the psychosocial burden of skin disease among skin of color consumers, treatment of lichen pl … 
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat rheumatoid arthritis and psoriatic arthritis, but was recently FDA approved i …